SynthesisTranslational psychiatry2025
Recent developments in omics studies and artificial intelligence in depression and suicide.
Synthesis in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A Cross-Matrix Peripheral Transcriptional Signature in Suicide Attempt:International journal of molecular sciences · 2026Article
- Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.The international journal of neuropsychopharmacology · 2026Review
- Cross-Platform and cross-species lipidomic profiling identifies promising biomarkers for adolescent major depressive disorder.Molecular psychiatry · 2026Article
- Decoding causal m6A: a bioinformatics roadmap for psychiatric disorders.Briefings in bioinformatics · 2026Review
- Symptom-specific genetics reveal heterogeneity within major depressive disorder.medRxiv : the preprint server for health sciences · 2026Article
- Progress and challenges in exploring the pathogenesis of depressive disorders via RNA sequencing.Frontiers in genetics · 2026Review
- 25 years of applying the 3Rs principles in safety pharmacology: success stories and future perspectives.Frontiers in physiology · 2026Review
- Artificial Intelligence-Based Methods and Omics for Mental Illness Diagnosis: A Review.Bioengineering (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Major depressive disorder (MDD) is the most prevalent and severe form of mental illness and is significantly linked to suicide. At present, addressing the treatment and prevention of depression and suicide poses significant challenges, largely due to the remaining uncertainties surrounding their pathogenesis. Thus, there is an urgent need to find new molecular pathways, as well as effective biomarkers and drug targets, to provide effective diagnosis, prognosis, and treatments for depression and suicide. Recent advancements in high-throughput sequencing technology and whole-genome analysis have enabled the collection of extensive omics data from blood samples, human autopsy brain tissue, and various animal models. This data captures significant molecular-level changes, including alterations in gene transcripts, epigenomes, and proteins, effectively reflecting the biological state of the disease. This review provides a systematic overview of advancements in transcriptomics, non-coding RNA, and AI related to depression and suicide. It discusses new research approaches, such as spatial transcriptomics, addresses challenges connected to various research materials and methodologies, and proposes avenues for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.